Will AI Prior Authorization Streamline Care or Deepen Denials?

Patients and physicians alike have wrestled with the bureaucratic maze of prior authorization for years. The promise of AI prior authorization is to cut through paperwork, but the reality is more contentious.

AI prior authorization: potential catalyst or new obstacle?

A recent Reuters analysis notes that insurers are piloting algorithms to flag clearly eligible claims, aiming to shave days off wait times. Yet, a 2025 AMA survey found ↓ 61% of doctors fear AI will increase wrongful denials of necessary treatments.

“If the system denies a life‑saving drug because an algorithm misinterprets the note, the patient pays the price,” a senior oncologist warned.

The tension mirrors post‑pandemic reforms that accelerated digital health tools without fully testing safeguards. Proponents argue that machine learning can instantly cross‑reference clinical guidelines, drug formularies, and patient histories, delivering instant green lights for routine prescriptions. Critics counter that opaque models may embed bias, leading insurers to reject borderline cases en masse. As hospitals invest in AI platforms, the stakes rise: a mis‑flagged claim could delay chemotherapy, while an approved claim could inflate costs if alternatives are overlooked. Stakeholders are calling for transparent audit trails, clinician‑in‑the‑loop checkpoints, and federal oversight before AI prior authorization scales nationwide.